HRSA Rural Health Clinic

COVID-19 Therapeutic Treatment Program FAQs

General

1. What is the HRSA RHC COVID-19 Therapeutic Treatment Program?
   This program provides CMS-certified RHCs free access to COVID-19 therapeutics. HRSA implemented this program to ensure underserved communities and those disproportionately affected by COVID-19 have equitable access to FDA-authorized or approved COVID-19 therapeutics.
2. Are RHCs required to participate in this program?
   No, eligible RHCs can choose to enroll and register in this program but are not required to do so.
3. Which therapeutics are distributed through this program?
   Paxlovid and Lagevrio (monulpiravir). 
4. Who can enroll in this program?
   Therapeutics Program enrollment is currently open to CMS-certified Rural Health Clinics enrolled in the HRSA COVID-19 Testing Supply or Vaccine Distribution Programs. For additional information please email RHCTreatment@HRSA.gov.

Program Policies

1. Are there any reporting requirements?
   RHCs are required to enter the number of therapeutics dispensed (“courses administered”) and inventory/stock on hand (“courses available”) weekly in TPOP. This data should be logged even if your RHC is not placing a new order or the stock on hand is zero.
   
   TPOP also has a wastage report feature for therapeutics to help HRSA keep track of the therapeutics wasted, the number of doses wasted, and understand how they were wasted. 
   
   
2. Can I give therapeutics to other clinics/hospitals?
   You may share therapeutics with other HRSA-approved locations that you have an established formal contract or agreement with that meet legal pharmaceutical requirements. Also, you can share stock with other organizations enrolled in this program.